Since Pola has significantly improved progression-free survival (PFS) in previously untreated DLBCL, as demonstrated in the phase III POLARIX study (12), it may represent a promising therapeutic option for refractory PTLD. This evidence concerns the gene POLA1 and post-transplant lymphoproliferative disease.